Radiotherapy plays an essential role in the function-preserving treatment of elderly patients with laryngeal cancer. Regarding early glottic cancer (GC), accelerated fractionated radiotherapy (Ax) is believed to be a useful treatment option for GC because of its convenience in reducing the treatment time, cost, and labor. In JCOG 0701, Ax showed comparable efficacy and safety to standard fractionated radiotherapy. In addition, real-world data and evidence from clinical research have also shown promising findings concerning Ax for GC. Regarding radiation techniques for advanced laryngeal cancer, intensity-modulated radiation therapy (IMRT) is very useful for reducing late toxicity, especially for concurrent chemoradiotherapy (CCRT). Less-invasive treatment using IMRT is now being evaluated in many on-going trials, and the JCOG1912 trial has just started to assess the non-inferiority in less-invasive treatment in CCRT using IMRT for locally advanced head and neck cancer. We herein report the results of our organized prospective observation study for patients using radiotherapy with cetuximab in the JROSG12-2 trial. I sincerely appreciate the opportunity to introduce our findings at the 33rd annual meeting of the Japan Laryngological Association.